AZ bites back at rivals with new Farxiga data in heart failure

AZ bites back at rivals with new Farxiga data in heart failure

Source: 
Pharmaforum
snippet: 

AstraZeneca’s SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli Lilly.